

June 2011 / Special Alert

Related Practices

- Appellate
- Class Actions
- Corporate Governance
- Mutual Funds
- Securities and Shareholder Litigation

A legal update from Dechert's Financial Services and White Collar and Securities Litigation Groups

The United States Supreme Court Declines to Expand the Scope of Primary Liability Under Rule 10b-5 to Service Providers Who Do Not Have Ultimate Authority Over Statements

In *Janus Capital Group, Inc. v. First Derivative Traders*,¹ the Supreme Court addressed the scope of primary liability in private actions under Rule 10b-5² (promulgated pursuant to Section 10(b) of the Securities Exchange Act of 1934 ("1934 Act"))³ of persons and entities that assist in the preparation or dissemination of a separate entity's prospectus or other public statements for misstatements in such documents.

In a five-to-four decision authored by Justice Thomas, the Court on June 13, 2011 took a narrow approach to the implied private right of action under Rule 10b-5, holding that persons and entities involved in the preparation and dissemination of public statements and filings do not "make" a false statement unless they have "ultimate authority over the [false] statement, including its content and whether and how to communicate it."⁴ Accordingly, the Court held that persons and entities lacking such authority cannot be held liable as primary

violators of Section 10(b) of the 1934 Act and Rule 10b-5 thereunder.

Although the decision addressed a claim of primary liability against an investment adviser of a registered investment company, the bright-line test the Court endorsed seems certain to narrow the exposure of other service providers, such as attorneys, accountants and administrators, to registered funds and other registrants to private civil actions for securities fraud under Rule 10b-5 relating to their involvement with statements and filings subject to the federal securities laws.

Discussion

Background

Petitioner/defendant Janus Capital Management LLC ("JCM") is the investment adviser to the Janus funds. Respondent/plaintiff First Derivative Traders ("First Derivative"), representing a putative class of shareholders in JCM's publicly traded corporate parent, Janus Capital Group Inc. ("JCG"), alleged that JCM had "made" certain misleading statements regarding market timing practices in the prospectuses for the Janus Investment Fund (the "Fund") based on its participation in writing and disseminating the prospectuses that contained the allegedly misleading statements.

¹ No. 09-525, slip op. at 8 (U.S. June 13, 2011).

² 17 C.F.R. 240.10b-5. The relevant portion of Rule 10b-5 prohibits the "mak[ing] of any untrue statement of a material fact . . . in connection with the purchase or sale of securities."

³ 15 U.S.C. § 78j(b).

⁴ *Janus Capital Group, Inc. v. First Derivative Traders*, No. 09-525, slip op. at 6 (U.S. June 13, 2011).

First Derivative alleged that those statements falsely represented that the Fund's investment adviser did not permit, and took active measures to prevent, market timing activities by investors in the Funds. Contending that the plaintiffs had bought JCG shares at inflated prices and thereafter lost money when market timing practices authorized by JCG and JCM became known to the public, First Derivative sought to hold JCM liable for fraud under Section 10(b) of the 1934 Act and Rule 10b-5. In addition, the plaintiffs alleged that JCG was liable under Section 20(a) of the 1934 Act as a control person of JCM.

The district court granted the defendants' motion to dismiss pursuant to Rule 12(b)(6), holding that the plaintiffs had failed to state a claim against JCM under Section 10(b) of the 1934 Act. The district court also ruled that the plaintiffs' claim of control person liability against JCG pursuant to Section 20(a) of the 1934 Act had to be dismissed because the plaintiffs had failed to plead a viable Section 10(b) claim against JCM.⁵

On appeal, the Fourth Circuit reversed the district court's ruling, holding that an adviser who "helped draft the misleading prospectuses" of a mutual fund could be held primarily liable under Section 10(b) of the 1934 Act.⁶ Thus, the Fourth Circuit permitted the plaintiffs' Section 10(b) primary liability claim against JCM and Section 20(a) control person liability claim against JCG to continue.⁷

The Supreme Court reversed the decision of the Fourth Circuit, holding that, for purposes of Rule 10b-5, any false statements in the Fund's prospectuses were made by the Fund, not by JCM. The Court reasoned that, while JCM may have been significantly involved in preparing the Fund's prospectuses, "this assistance, subject to the ultimate control of the Janus Investment Fund, does not mean that JCM 'made' any statement in the Janus Investment Fund's prospectuses."⁸ This is so, the Court held, because JCM did not have "ultimate

⁵ *In re Mutual Funds Inv. Litigation*, 487 F. Supp. 2d 618, 620 (D. Md. 2007).

⁶ *In re Mutual Funds Inv. Litigation*, 566 F. 3d 111, 121 (4th Cir. 2009).

⁷ *Id.* at 115.

⁸ *Janus Capital Group, Inc. v. First Derivative Traders*, No. 09-525, slip op. at 12 (U.S. June 13, 2011).

authority over the statement, including its content and whether and how to communicate it."⁹

The Court "decline[d] [the] invitation to disregard the corporate form"¹⁰ and noted that "JCM and Janus Investment Fund remain legally separate entities."¹¹ Further, the Court observed that "[a]ny reapportionment of liability in the securities industry in light of the close relationship between the investment advisers and mutual funds is properly the responsibility of Congress and not the courts."¹²

A Bright Line Test for Primary Liability under Rule 10b-5

Because the private right of action recognized under Section 10(b) and Rule 10b-5 is only implied and not expressly provided by statute,¹³ the Supreme Court was "mindful that [the Court] must give 'narrow dimensions' . . . to a right of action Congress did not authorize when it first enacted the statute and did not expand when it revisited the law."¹⁴

Consistent with that view, in recent years the Court has repeatedly declined to expand the scope of the private right of action under Section 10(b) and Rule 10b-5 to include claims against persons other than those who are primary violators (i.e., those who "make" a false statement as opposed to those who aid and abet the maker of the false statement).¹⁵ *Janus* continues this

⁹ *Id.* at 6.

¹⁰ *Id.* at 9.

¹¹ *Id.* at 10.

¹² *Id.*

¹³ *Superintendent of Ins. of N. Y. v. Bankers Life & Casualty Co.*, 404 U.S. 6, 13 n.9 (1971).

¹⁴ *Janus Capital Group, Inc. v. First Derivative Traders*, No. 09-525, slip op. at 6 (quoting *Stoneridge Inv. Partners, LLC v. Scientific-Atlanta, Inc.*, 552 U.S. 148, 167 (2008)).

¹⁵ See *Central Bank of Denver, N.A. v. First Interstate Bank of Denver, N.A.*, 511 U.S. 164, 191 (1994) (stating that "[b]ecause the text of § 10(b) does not prohibit aiding and abetting, we hold that a private plaintiff may not maintain an aiding and abetting suit under § 10(b)"); see also *Stoneridge Inv. Partners, LLC v. Scientific-Atlanta, Inc.*, 552 U.S. 148, 158, 166 (2008) (stating that Section 10(b)'s private right of action "does not extend to aiders and abettors," but it "continues to cover secondary actors who commit primary violations.").

trend, drawing a “clean line” between those who are primarily liable and those who are secondarily liable, by limiting the scope of persons who may be sued for “making” allegedly false statements to those “with ultimate authority” over the statements.¹⁶

In affirming its bright-line test for liability under Rule 10b-5, the Court rejected the more flexible, fact-specific test previously adopted by the Fourth Circuit and supported by the Department of Justice (“DOJ”) and the Securities and Exchange Commission (“SEC”) on behalf of the United States as *amicus curiae*. The SEC and DOJ argued that the term “make” should provide for primary liability when “a person ‘creates’ a misrepresentation either by writing or speaking it, providing false or misleading information for another to put into it, or allowing it to be attributed to him.”¹⁷ The Court concluded that this view was inconsistent with its prior rulings limiting the scope of primary civil liability.¹⁸

Corporate Form Respected

In support of its arguments that JCM should be primarily liable for the alleged false statements in the Fund’s prospectus, First Derivative contended that, because of the “‘well recognized and uniquely close relationship’ between a mutual fund and its investment adviser[,] . . . an investment adviser should generally be understood to be the ‘maker’ of statements by its client mutual fund, like a playwright whose lines are delivered by an actor.”¹⁹ The DOJ and SEC again supported First Derivative, arguing to the Court that “[a]lthough JCM was subject to oversight by the [Fund’s] trustees, it allegedly performed the ‘insider’ functions that corporate officers and employees ordinarily would, rather than the advisory role typically associated with outside service providers. Thus, JCM can be held liable for its own statements to the market, made ‘directly or

indirectly’ through the prospectuses of the Funds over which it exercised managerial control.”²⁰

The Court turned these arguments aside as well because they “disregard the corporate form”²¹ and “would also lead to results inconsistent with our precedent.”²² The Court stated that “JCM and [the Fund] remain legally separate entities and [the Fund’s] board of trustees was more independent than the statute requires.”²³ The Court added that “[a]ny reapportionment of liability in the securities industry in light of the close relationship between investment advisers and mutual funds is properly the responsibility of Congress and not the courts.”²⁴

Implications of *Janus Capital*

Janus Capital raises the bar for claims of primary liability in private civil actions under Section 10(b) and Rule 10b-5 for misleading statements, by limiting the potential defendants to those that actually “make” the misleading statement at issue. Persons or entities that assist or participate in the preparation or dissemination of filings or statements by public registrants, but who lack the “ultimate authority” over a statement made, cannot be held liable under the decision’s bright-line test.

■ ■ ■

This update was authored by William K. Dodds (+1 212 698 3557; william.dodds@dechert.com), Ruth Epstein (+1 202 261 3322; ruth.epstein@dechert.com); Jane A. Kanter (+1 202 261 3302; jane.kanter@dechert.com) and Evan S. Posner (+1 860 524 3922; evan.posner@dechert.com).

¹⁶ *Janus Capital Group, Inc. v. First Derivative Traders*, No. 09-525, slip op. at 7 n.6 (U.S. June 13, 2011).

¹⁷ Brief for United States as *Amicus Curiae* Supporting Respondents at 8, *Janus Capital Group, Inc. v. First Derivative Traders*, No. 09-525, slip op. (U.S. June 13, 2011).

¹⁸ *Janus Capital Group, Inc. v. First Derivative Traders*, No. 09-525, slip op. at 9 (U.S. June 13, 2011).

¹⁹ *Id.* (citation omitted).

²⁰ Brief for United States as *Amicus Curiae* Supporting Respondents at 10, *Janus Capital Group, Inc. v. First Derivative Traders*, No. 09-525, slip op. (U.S. June 13, 2011).

²¹ *Janus Capital Group, Inc. v. First Derivative Traders*, No. 09-525, slip op. at 9 (U.S. June 13, 2011).

²² *Id.* at 8.

²³ *Id.* at 10.

²⁴ *Id.*

Practice group contacts

For more information, please contact the authors, one of the attorneys listed or any Dechert attorney with whom you regularly work. Visit us at www.dechert.com/financial_services and www.dechert.com/white_collar.

If you would like to receive any of our other *DechertOnPoints*, please [click here](#).

Karen L. Anderberg
London
+44 20 7184 7313
karen.anderberg@dechert.com

G. Eric Brunstad, Jr.
Hartford
+1 860 524 3960
eric.brunstad@dechert.com

Joseph F. Donley
New York
+1 212 649 8724
joseph.donley@dechert.com

David L. Ansell
Washington, D.C.
+1 202 261 3433
david.ansell@dechert.com

Kevin F. Cahill
Orange County
+1 949 442 6051
kevin.cahill@dechert.com

Steven A. Engel
Washington, D.C.
+1 202 261 3403
steven.engel@dechert.com

Margaret A. Bancroft
New York
+1 212 698 3590
margaret.bancroft@dechert.com

Christopher D. Christian
Boston
+1 617 728 7173
christopher.christian@dechert.com

Ruth S. Epstein
Washington, D.C.
+1 202 261 3322
ruth.epstein@dechert.com

Sander M. Bieber
Washington, D.C.
+1 202 261 3308
sander.bieber@dechert.com

David C. Chu
Hong Kong
+852 3518 4778
david.chu@dechert.com

Steven B. Feirson
Philadelphia
+1 215 994 2489
steven.feirson@dechert.com

Stephen H. Bier
New York
+1 212 698 3889
stephen.bier@dechert.com

Robert A. Cohen
New York
+1 212 698 3501
robert.cohen@dechert.com

Joseph R. Fleming
Boston
+1 617 728 7161
joseph.fleming@dechert.com

Thomas C. Bogle
Washington, D.C.
+1 202 261 3360
thomas.bogle@dechert.com

Elliott R. Curzon
Washington, D.C.
+1 202 261 3341
elliott.curzon@dechert.com

Brendan C. Fox
Washington, D.C.
+1 202 261 3381
brendan.fox@dechert.com

Catherine Botticelli
Washington, D.C.
+1 202 261 3368
catherine.botticelli@dechert.com

Douglas P. Dick
Washington, D.C.
+1 202 261 3305
douglas.dick@dechert.com

Robert Friedman
New York
+1 212 649 8735
robert.friedman@dechert.com

Stephen D. Brown
Philadelphia
+1 215 994 2240
stephen.brown@dechert.com

William K. Dodds
New York
+1 212 698 3557
william.dodds@dechert.com

David M. Geffen
Boston
+1 617 728 7112
david.geffen@dechert.com

Julien Bourgeois
Washington, D.C.
+1 202 261 3451
julien.bourgeois@dechert.com

Michael S. Doluisio
Philadelphia
+1 215 994 2325
michael.doluisio@dechert.com

Michael J. Gilbert
New York
+1 212 698 3886
michael.gilbert@dechert.com

David J. Harris
Washington, D.C.
+1 202 261 3385
david.harris@dechert.com

Christopher P. Harvey
Boston
+1 617 728 7167
christopher.harvey@dechert.com

Robert C. Heim
Philadelphia
+1 215 994 2570
robert.heim@dechert.com

Robert W. Helm
Washington, D.C.
+1 202 261 3356
robert.helm@dechert.com

Frederick G. Herold
Silicon Valley
+1 650 813 4930
frederick.herold@dechert.com

Richard M. Hervey
New York
+1 212 698 3568
richard.hervey@dechert.com

David S. Hoffner
New York
+1 212 649 8781
david.hoffner@dechert.com

Richard Horowitz
New York
+1 212 698 3525
richard.horowitz@dechert.com

Nicolle L. Jacoby
New York
+1 212 698 3820
nicolle.jacoby@dechert.com

Robert J. Jossen
New York
+1 212 698 3639
robert.jossen@dechert.com

Jane A. Kanter
Washington, D.C.
+1 202 261 3302
jane.kanter@dechert.com

Geoffrey R.T. Kenyon
Boston
+1 617 728 7126
geoffrey.kenyon@dechert.com

Matthew Kerfoot
New York
+1 212 641 5694
matthew.kerfoot@dechert.com

Michael L. Kichline
Philadelphia
+1 215 994 2439
michael.kichline@dechert.com

David A. Kotler
Princeton
+1 609 955 3226
david.kotler@dechert.com

Cheryl A. Krause
Philadelphia
+1 215 994 2139
cheryl.krause@dechert.com

Matthew L. Larrabee
San Francisco
+1 415 262 4579
matthew.larrabee@dechert.com

Robert H. Ledig
Washington, D.C.
+1 202 261 3454
robert.ledig@dechert.com

Thomas H. Lee II
Philadelphia
+1 215 994 2994
thomas.lee@dechert.com

Andrew J. Levander
New York
+1 212 698 3683
andrew.levander@dechert.com

Angelyn Lim
Hong Kong
+852 3518 4718
angelyn.lim@dechert.com

Kathleen N. Massey
New York
+1 212 698 3686
kathleen.massey@dechert.com

George J. Mazin
New York
+1 212 698 3570
george.mazin@dechert.com

Edward A. McDonald
New York
+1 212 698 3672
edward.mcdonald@dechert.com

Gary J. Mennitt
New York
+1 212 698 3831
gary.mennitt@dechert.com

Gordon L. Miller
Washington, D.C.
+1 202 261 3467
gordon.miller@dechert.com

Jack W. Murphy
Washington, D.C.
+1 202 261 3303
jack.murphy@dechert.com

Kevin J. O'Brien
New York
+1 212 698 3697
kevin.obrien@dechert.com

John V. O'Hanlon
Boston
+1 617 728 7111
john.ohanlon@dechert.com

William W. Oxley
Los Angeles
+1 213 808 5712
william.oxley@dechert.com

Reza Pishva
Washington, D.C.
+1 202 261 3459
reza.pishva@dechert.com

Edward L. Pittman
Washington, D.C.
+1 202 261 3387
edward.pittman@dechert.com

Charles I. Poret
New York
+1 212 698 3532
charles.poret@dechert.com

Jeffrey S. Poretz
Washington, D.C.
+1 202 261 3358
jeffrey.poretz@dechert.com

Jon S. Rand
New York
+1 212 698 3634
jon.rand@dechert.com

Robert A. Robertson
Orange County
+1 949 442 6037
robert.robertson@dechert.com

Keith T. Robinson
Hong Kong
+1 852 3518 4705
keith.robinson@dechert.com

Benjamin E. Rosenberg
New York
+1 212 698 3606
benjamin.rosenberg@dechert.com

Christopher S. Ruhland
Los Angeles
+1 213 808 5714
christopher.ruhland@dechert.com

Kevin P. Scanlan
New York
+1 212 649 8716
kevin.scanlan@dechert.com

Jeremy I. Senderowicz
New York
+1 212 641 5669
jeremy.senderowicz@dechert.com

Frederick H. Sherley
Charlotte
+1 704 339 3100
frederick.sherley@dechert.com

Michael L. Sherman
Washington, D.C.
+1 202 261 3449
michael.sherman@dechert.com

Neil A. Steiner
New York
+1 212 698 3822
neil.steiner@dechert.com

Stuart Strauss
New York
+1 212 698 3529
stuart.strauss@dechert.com

Patrick W. D. Turley
Washington, D.C.
+1 202 261 3364
patrick.turley@dechert.com

Claude M. Tusk
New York
+1 212 698 3612
claudetusk@dechert.com

Thomas P. Vartanian
Washington, D.C.
+1 202 261 3439
thomas.vartanian@dechert.com

Brian S. Vargo
Philadelphia
+1 215 994 2880
brian.vargo@dechert.com

Adam J. Wasserman
New York
+1 212 698 3580
adam.wasserman@dechert.com

M. Holland West
New York
+1 212 698 3527
holland.west@dechert.com

Andrew S. Wong
Los Angeles
+1 213 808 5710
andrew.wong@dechert.com

Jennifer Wood
London
+44 20 7184 7403
jennifer.wood@dechert.com

Edwin V. Woodsome
Los Angeles
+1 213 808 5711
edwin.woodsomes@dechert.com

Anthony H. Zacharski
Hartford
+1 860 524 3937
anthony.zacharski@dechert.com